183 related articles for article (PubMed ID: 31896813)
1. Regulation of pancreatic cancer TRAIL resistance by protein O-GlcNAcylation.
Yang SZ; Xu F; Yuan K; Sun Y; Zhou T; Zhao X; McDonald JM; Chen Y
Lab Invest; 2020 May; 100(5):777-785. PubMed ID: 31896813
[TBL] [Abstract][Full Text] [Related]
2. DR4-Ser424
Lee H; Oh Y; Jeon YJ; Lee SY; Kim H; Lee HJ; Jung YK
Cancer Res; 2019 Jun; 79(11):2839-2852. PubMed ID: 30987996
[TBL] [Abstract][Full Text] [Related]
3. PARP-1 regulates resistance of pancreatic cancer to TRAIL therapy.
Yuan K; Sun Y; Zhou T; McDonald J; Chen Y
Clin Cancer Res; 2013 Sep; 19(17):4750-9. PubMed ID: 23833311
[TBL] [Abstract][Full Text] [Related]
4. The long non-coding RNA HOTAIR enhances pancreatic cancer resistance to TNF-related apoptosis-inducing ligand.
Yang SZ; Xu F; Zhou T; Zhao X; McDonald JM; Chen Y
J Biol Chem; 2017 Jun; 292(25):10390-10397. PubMed ID: 28476883
[TBL] [Abstract][Full Text] [Related]
5. Calmodulin antagonists promote TRA-8 therapy of resistant pancreatic cancer.
Yuan K; Yong S; Xu F; Zhou T; McDonald JM; Chen Y
Oncotarget; 2015 Sep; 6(28):25308-19. PubMed ID: 26320171
[TBL] [Abstract][Full Text] [Related]
6. OSMI-1 Enhances TRAIL-Induced Apoptosis through ER Stress and NF-κB Signaling in Colon Cancer Cells.
Lee SJ; Lee DE; Choi SY; Kwon OS
Int J Mol Sci; 2021 Oct; 22(20):. PubMed ID: 34681736
[TBL] [Abstract][Full Text] [Related]
7. DR4 specific TRAIL variants are more efficacious than wild-type TRAIL in pancreatic cancer.
Yu R; Albarenque SM; Cool RH; Quax WJ; Mohr A; Zwacka RM
Cancer Biol Ther; 2014; 15(12):1658-66. PubMed ID: 25482930
[TBL] [Abstract][Full Text] [Related]
8. Elevated O-GlcNAcylation promotes gastric cancer cells proliferation by modulating cell cycle related proteins and ERK 1/2 signaling.
Jiang M; Qiu Z; Zhang S; Fan X; Cai X; Xu B; Li X; Zhou J; Zhang X; Chu Y; Wang W; Liang J; Horvath T; Yang X; Wu K; Nie Y; Fan D
Oncotarget; 2016 Sep; 7(38):61390-61402. PubMed ID: 27542217
[TBL] [Abstract][Full Text] [Related]
9. Transcriptional regulation of
Qian K; Wang S; Fu M; Zhou J; Singh JP; Li MD; Yang Y; Zhang K; Wu J; Nie Y; Ruan HB; Yang X
J Biol Chem; 2018 Sep; 293(36):13989-14000. PubMed ID: 30037904
[TBL] [Abstract][Full Text] [Related]
10. SHCBP1 interacting with EOGT enhances O-GlcNAcylation of NOTCH1 and promotes the development of pancreatic cancer.
Yang C; Hu JF; Zhan Q; Wang ZW; Li G; Pan JJ; Huang L; Liao CY; Huang Y; Tian YF; Shen BY; Chen JZ; Wang YD; Chen S
Genomics; 2021 Mar; 113(2):827-842. PubMed ID: 33515675
[TBL] [Abstract][Full Text] [Related]
11. N-Acetyl-Glucosamine Sensitizes Non-Small Cell Lung Cancer Cells to TRAIL-Induced Apoptosis by Activating Death Receptor 5.
Liang Y; Xu W; Liu S; Chi J; Zhang J; Sui A; Wang L; Liang Z; Li D; Chen Y; Niu H
Cell Physiol Biochem; 2018; 45(5):2054-2070. PubMed ID: 29533936
[TBL] [Abstract][Full Text] [Related]
12. Cytoplasmic PARP-1 promotes pancreatic cancer tumorigenesis and resistance.
Xu F; Sun Y; Yang SZ; Zhou T; Jhala N; McDonald J; Chen Y
Int J Cancer; 2019 Jul; 145(2):474-483. PubMed ID: 30614530
[TBL] [Abstract][Full Text] [Related]
13. mTOR/MYC Axis Regulates O-GlcNAc Transferase Expression and O-GlcNAcylation in Breast Cancer.
Sodi VL; Khaku S; Krutilina R; Schwab LP; Vocadlo DJ; Seagroves TN; Reginato MJ
Mol Cancer Res; 2015 May; 13(5):923-33. PubMed ID: 25636967
[TBL] [Abstract][Full Text] [Related]
14. Decreasing O-GlcNAcylation affects the malignant transformation of MCF-7 cells via Hsp27 expression and its O-GlcNAc modification.
Netsirisawan P; Chaiyawat P; Chokchaichamnankit D; Lirdprapamongkol K; Srisomsap C; Svasti J; Champattanachai V
Oncol Rep; 2018 Oct; 40(4):2193-2205. PubMed ID: 30106436
[TBL] [Abstract][Full Text] [Related]
15. OGT-mediated O-GlcNAcylation promotes NF-κB activation and inflammation in acute pancreatitis.
Zhang D; Cai Y; Chen M; Gao L; Shen Y; Huang Z
Inflamm Res; 2015 Dec; 64(12):943-52. PubMed ID: 26407569
[TBL] [Abstract][Full Text] [Related]
16. A novel TRAIL mutant-TRAIL-Mu3 enhances the antitumor effects by the increased affinity and the up-expression of DR5 in pancreatic cancer.
Huang M; Zhu H; Yi C; Yan J; Wei L; Yang X; Chen S; Huang Y
Cancer Chemother Pharmacol; 2018 Nov; 82(5):829-838. PubMed ID: 30167846
[TBL] [Abstract][Full Text] [Related]
17. Death receptor 5 is activated by fucosylation in colon cancer cells.
Zhang B; van Roosmalen IAM; Reis CR; Setroikromo R; Quax WJ
FEBS J; 2019 Feb; 286(3):555-571. PubMed ID: 30589515
[TBL] [Abstract][Full Text] [Related]
18. Suppressed OGT expression inhibits cell proliferation while inducing cell apoptosis in bladder cancer.
Wang L; Chen S; Zhang Z; Zhang J; Mao S; Zheng J; Xuan Y; Liu M; Cai K; Zhang W; Guo Y; Zhai W; Yao X
BMC Cancer; 2018 Nov; 18(1):1141. PubMed ID: 30453909
[TBL] [Abstract][Full Text] [Related]
19. O-GlcNAcylation regulates cancer metabolism and survival stress signaling via regulation of the HIF-1 pathway.
Ferrer CM; Lynch TP; Sodi VL; Falcone JN; Schwab LP; Peacock DL; Vocadlo DJ; Seagroves TN; Reginato MJ
Mol Cell; 2014 Jun; 54(5):820-31. PubMed ID: 24857547
[TBL] [Abstract][Full Text] [Related]
20. O-GlcNAcylation plays a role in tumor recurrence of hepatocellular carcinoma following liver transplantation.
Zhu Q; Zhou L; Yang Z; Lai M; Xie H; Wu L; Xing C; Zhang F; Zheng S
Med Oncol; 2012 Jun; 29(2):985-93. PubMed ID: 21461968
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
